Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2018-05-01 | Forward | 5:1 |
Genmab A/S, based in Denmark, develops antibody therapeutics for cancer and other diseases, with marketed products like DARZALEX and teprotumumab, and a broad pipeline including Phase 2 and preclinical programs through collaborations worldwide.
An injectable prescription medicine for adults with certain relapsed or refractory large B-cell and follicular lymphoma, exemplifying Genmab’s successful development of innovative antibody therapies.
Genmab initiated and completed a tender offer to acquire Merus N.V., a clinical-stage biotechnology company, for approximately $8.0 billion. [4] This strategic acquisition adds the late-stage asset petosemtamab to Genmab's portfolio, which has shown promise in head and neck cancer, significantly accelerating the company's transition to a wholly owned product model and aiming to drive sustained growth. [12, 14, 36]
Genmab made its most significant strategic move to date with the proposed $8 billion acquisition of Merus N.V. This transaction is designed to meaningfully accelerate Genmab's shift from a royalty-dependent business model to a fully integrated biotechnology company with a diversified and wholly-owned product pipeline.
Genmab delivered strong topline results for Epkinly in frontline DLBCL, showing a 51% reduction in risk of progression or death. Epkinly's efficacy notably exceeds Roche's Polivy in similar settings, positioning GMAB as a potential market leader among T-cell engagers. Frontline DLBCL represents the key growth driver for Epkinly, and I see upside to the company's $3 billion+ peak sales guidance based on better-than-expected treatment effect.
ABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III study's PFS goal.
Genmab (GMAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
The Danish company said the Epkinly drug helped extend the time patients with a common type of lymphoma lived.
[url="]Genmab A/S[/url](Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed tr
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the topline results, Genmab and AbbVie will engage global regulatory authorities NORTH CHICAGO, Ill. and COPENHAGEN, Denmark, Oct. 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of 2 to 5.
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diff.
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOLâ¢-01 trial evaluating rinatabart sesutecan (Rina-S), an inv
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 2, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Darwin Global Management Limited (“Darwin”) has informed us that, as of September 28, 2026, Darwin through shares and ADRs held by certain investment funds and portfolios for which Darwin acts as investment manager, controls the voting rights attached to 3,188,361 shares in Genmab A/S, corresponding to 5.11% of the voting rights in Genmab A/S. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines.
Overall rating: B
| PEER | PRICE | |
|---|---|---|
 ILMN | $276.62 | COMPARE |
 ROIV | $35.06 | COMPARE |
 DGX | $228.06 | COMPARE |
 RPRX | $56.54 | COMPARE |
 BNTX | $96.14 | COMPARE |
 UTHR | $544.54 | COMPARE |
 INCY | $113.69 | COMPARE |
 THC | $261.33 | COMPARE |
